Showing 101-120 of 258 for: EBMG evidence summaries > Pharmacotherapeutics 
- Corticosteroids for maintaining remission of Crohn's disease
EBMG evidence summaries, 12-Mar-2009
The use of corticosteroids does probably not significantly reduce the risk of relapse over a 24 month period of follow-up.
- Corticosteroids for myasthenia gravis
EBMG evidence summaries, 13-Sep-2011
Corticosteroid treatment may have short-term benefit in myasthenia gravis compared with placebo.
- Corticosteroids for nephrotic syndrome in children
EBMG evidence summaries, 25-Feb-2008
Prednisone for at least three months is more effective than shorter courses in preventing relapses in children with nephrotic syndrome. Six months of therapy appears to result in a reduced risk for relapse without increase in adverse effects.
- Corticosteroids for nerve damage in leprosy
EBMG evidence summaries, 28-Jan-2010
Prednisolone appears not to improve nerve function in patients with sensory impairment in leprosy.
- Corticosteroids for preventing relapse following acute exacerbations of asthma
EBMG evidence summaries, 15-Jan-2008
A short course of corticosteroids following assessment for an acute exacerbation of asthma reduces the number of relapses and decreases beta-agonist use without an apparent increase in side effects.
- Corticosteroids for pulmonary sarcoidosis
EBMG evidence summaries, 28-Jan-2010
Oral corticosteroids improve chest X-ray, symptoms and spirometry over 3–24 months in patients with pulmonary sarcoidosis. In stage II–III disease, inhaled corticosteroids can be used for maintenance therapy and the 5-year prognosis may be improved in ter
- Corticosteroids for subarachnoid or intracerebral haemorrhage
EBMG evidence summaries, 31-Aug-2005
There is no evidence of a beneficial or adverse effect of corticosteroids in patients with either subarachnoid haemorrhage or primary intracerebral haemorrhage.
- Corticosteroids for the resolution of malignant bowel obstruction
EBMG evidence summaries, 10-May-2008
Dexamethasone intravenously may help to resolve malignant bowel obstruction.
- Corticosteroids for treating severe sepsis and septic shock
EBMG evidence summaries, 27-Aug-2007
Low dose of corticosteroids for five days is effective in improving survival in septic shock without causing harm.
- Corticosteroids in IgA nephropathy
EBMG evidence summaries, 8-Apr-2004
A 6-month course of steroid treatment appears to protect against deterioration in renal function in IgA nephropathy.
- Corticosteroids in the treatment of seborrhoeic dermatitis
EBMG evidence summaries, 5-Aug-2003
Corticosteroids may be at least as effective as ketoconazole in the treatment of seborrhoeic dermatitis of the scalp and may have a more rapid start of action.
- Corticosteroids or ACTH for acute exacerbations in multiple sclerosis
EBMG evidence summaries, 11-Nov-2009
High dose methylprednisolone appears to accelarate the recovery from multiple sclerosis relapses.
- Dapsone as an oral corticosteroid sparing agent for asthma
EBMG evidence summaries, 28-Jan-2010
There is no evidence from randomized controlled trials of dapsone for steroid-dependent asthmatic patients.
- Decongestants and antihistamines for acute otitis media in children
EBMG evidence summaries, 21-Oct-2011
Use of decongestants and antihistamines for acute otitis media or otitis media with effusion in children does not improve clinically important outcomes but gives an increased risk of side effects.
- Diazepam for treating tetanus
EBMG evidence summaries, 1-Apr-2004
Diazepam alone may be more effective in treating tetanus than combination of phenobarbitone and chlorpromazine.
- Dietary calcium supplementation for preventing colorectal cancer
EBMG evidence summaries, 14-Oct-2010
Daily intake of 1 gr dietary calcium may have moderate protective effect on development of colorectal adenomatous polyps.
- Dietary fiber and hypertension
EBMG evidence summaries, 1-Apr-2007
Dietary fiber may slightly decrease blood pressure.
- Dietary fibre for the prevention of colorectal adenomas and carcinomas
EBMG evidence summaries, 5-Aug-2003
Dietary fibre may not be effective in the prevention of colorectal adenomas and carcinomas in the very short term (2 to 4 years follow up).
- Dietary fibre in the treatment of irritable bowel syndrome
EBMG evidence summaries, 7-Sep-2006
Soluble fibre improves overall symptoms and constipation but not abdominal pain in irritable bowel syndrome.
- Different antihypertensive agents as first line therapies
EBMG evidence summaries, 4-Dec-2009
Hypertension treatment with ACE-inhibitors, angiotensin-receptor blockers, beta blockers, calcium channel blockers, or low dose diuretics decreases cardiovascular events.
